BIOBRIEFPAPER
Order 818 is a Chinese rule adding a parallel review track for experimental cell, gene, and regenerative therapies, with a wider front door and a hard safety wall at the end.
China filed 112 clinical research projects for cell, gene, and regenerative therapies under a new dual-track regulatory framework in its first nine filing batches, according to a peer-reviewed review titled "China's Order 818: A New Commercialization Pathway Reshaping Cell and Gene Therapy," indexed on PubMed.
The framework, known as Order 818 and formally titled "Regulations on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies," adds a parallel track for frontier biomedical technologies alongside the conventional drug and device route. Cell therapies, gene editing, and regenerative medicine all fall under the new path. The rule took effect May 1, 2026, and it lets qualifying technologies move from clinical research into paid clinical use at approved hospitals without the usual national drug registration step, according to Morgan Lewis's summary of the regulation.
The design pairs a "wide entry" front door with a "strict exit" safety review. The wider threshold lets more experimental therapies enter clinical research. The back end is where regulators decide which projects reach patients.
The 112 are research-project submissions, not approvals. The dataset tracks what crossed the entry gate, not what cleared the safety wall. The framework's load-bearing claim is the exit, not the door.
The review's authors describe the architecture as a "transformative paradigm" and call China a global leader in clinical translation of these biotechnologies. Both are the review's framing, not an independent finding.
What remains unknown: whether the parallel track expands patient access to experimental therapies, or simply moves the same review work into a different lane.